HIGHLIGHTS
- who: Richa Dwivedi from the University of Pittsburgh, United States have published the article: APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants, in the Journal: (JOURNAL)
- what: The results from this study provide insight in how and why the enigmatic V179I substitution is selected in HIV-1 RT during NNRTI treatment.
SUMMARY
Nonnucleoside reverse_transcriptase inhibitors (NNRTIs) comprise a class of antiretroviral drugs that target the HIV-1 enzyme reverse_transcriptase (RT) that are used for both ART and PrEP. V179I . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.